journal
Journals Clinical Advances in Hematolog...

Clinical Advances in Hematology & Oncology : H&O

https://read.qxmd.com/read/36867558/management-of-toxicities-associated-with-immune-checkpoint-inhibitors
#1
REVIEW
Karen M Yun, Lyudmila Bazhenova
Immune-related adverse events (irAEs) encompass a diverse range of toxicities following treatment with immune checkpoint inhibitors (ICIs), each with distinctive symptoms, severities, and outcomes. irAEs can affect any organ and are potentially fatal, so early diagnosis is key in preventing serious events. irAEs can be fulminant, requiring immediate attention and intervention. Management of irAEs involves the use of systemic corticosteroids and immunosuppressive agents in addition to any disease-specific therapeutics...
March 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36867557/car-t-cell-therapy-for-cll-a-new-addition-to-our-treatment-toolbox
#2
REVIEW
Lorenzo Iovino, Mazyar Shadman
Treatment of high-risk chronic lymphocytic leukemia (CLL) has undergone a revolution in recent years with the introduction of novel agents. Bruton kinase inhibitors (BTK) inhibitors, such as ibrutinib, acalabrutinib, and zanubrutinib, are effective at controlling CLL in all lines of therapy, including in patients with high-risk features. BTK inhibitors can be used in sequence or in combination with the BCL2 inhibitor venetoclax. As a result, standard chemotherapy and allogeneic stem cell transplant (allo-SCT)-once major treatment approaches in high-risk patients-are used much less commonly in the current era...
March 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36867556/the-use-of-biomarkers-in-early-stage-nsclc
#3
Jae Y Kim
No abstract text is available yet for this article.
March 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36867555/new-evidence-for-neoadjuvant-therapy-in-advanced-melanoma
#4
Sapna P Patel
No abstract text is available yet for this article.
March 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36867554/novel-endocrine-therapy-agents-in-er-positive-her2-negative-breast-cancer
#5
Erika P Hamilton
No abstract text is available yet for this article.
March 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36867553/zandelisib-and-b-cell-lymphomas
#6
Andrew D Zelenetz
No abstract text is available yet for this article.
March 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36867552/factors-guiding-selection-of-treatment-in-metastatic-colorectal-cancer
#7
Leonard Saltz
No abstract text is available yet for this article.
March 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780476/noncovalent-btk-inhibitors-in-b-cell-lymphoma
#8
Catherine C Coombs
No abstract text is available yet for this article.
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780475/addressing-cardiovascular-complications-of-btk-inhibitors
#9
Javid Moslehi
No abstract text is available yet for this article.
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780474/new-staging-systems-in-nonmetastatic-prostate-cancer
#10
Felix Feng
No abstract text is available yet for this article.
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780473/a-review-of-essential-thrombocythemia-and-its-complications
#11
REVIEW
Rodrick Babakhanlou, Lucia Masarova, Srdan Verstovsek
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm characterized by an increased platelet count in the peripheral blood and excessive megakaryopoiesis in the bone marrow. In one-third of cases, the disease remains benign and does not lead to complications. In the remaining cases, however, ET may present with thromboembolic and hemorrhagic complications and transform into more aggressive myeloid neoplasms, with a negative effect on morbidity and mortality. Despite extensive research and a better understanding of the pathogenesis and etiology of the complications associated with ET, limited data are available on the management of complications and emergencies...
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780472/the-emerging-use-of-chemotherapy-free-regimens-in-adults-with-philadelphia-chromosome-positive-acute-lymphoblastic-leukemia
#12
REVIEW
Jacquelyn D Sawyers, Nadya J Jammal, Nicholas J Short, Hagop Kantarjian, Elias J Jabbour
Before the development of tyrosine kinase inhibitors (TKIs), the outcome of patients with a diagnosis of Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia was dismal. Combinations of TKIs and chemotherapy improved survival rates, but allogeneic stem cell transplant was still relied on to avoid relapse in most cases. More recently, the chemotherapy-free combination of blinatumomab plus newer-generation TKIs has shown favorable results and may eliminate the need for allogeneic stem cell transplant...
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780461/highlights-in-metastatic-breast-cancer-from-sabcs-2022
#13
JOURNAL ARTICLE
Hope S Rugo
No abstract text is available yet for this article.
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780460/highlights-in-metastatic-breast-cancer-from-the-2022-san-antonio-breast-cancer-symposium
#14
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780458/progress-in-the-treatment-of-breast-cancer-increased-survival-improved-patient-experience-and-advances-in-drug-formulation
#15
JOURNAL ARTICLE
Aditya Bardia
No abstract text is available yet for this article.
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36780457/progress-in-the-treatment-of-breast-cancer-increased-survival-improved-patient-experience-and-advances-in-drug-formulation
#16
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
February 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36638357/tumor-infiltrating-lymphocyte-therapy-in-metastatic-melanoma
#17
Jason A Chesney
No abstract text is available yet for this article.
January 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36638356/beyond-factor-replacement-therapy-new-and-experimental-agents-for-hemophilia
#18
Annette von Drygalski
No abstract text is available yet for this article.
January 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36638355/optimizing-the-benefits-of-bcma-targeted-car-t-cell-therapy-in-multiple-myeloma
#19
Sagar Lonial
No abstract text is available yet for this article.
January 2023: Clinical Advances in Hematology & Oncology: H&O
https://read.qxmd.com/read/36638354/how-we-treat-advanced-biliary-tract-cancers-in-the-second-line-setting
#20
JOURNAL ARTICLE
Haley Ellis, Srivatsan Raghavan, Brian M Wolpin, James M Cleary
No abstract text is available yet for this article.
January 2023: Clinical Advances in Hematology & Oncology: H&O
journal
journal
40386
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.